DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/hshg6b/retinal_vein) has announced the addition of the “Retinal Vein Occlusion – Pipeline Review, H1 2015” report to their offering. This report provides comprehe…
Category: Business
Aerie Pharmaceuticals Elects Julie McHugh and Michael M. du Toit to the Company’s Board of Directors
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that Julie McHugh and Michael M. du Toit have been elected to the Company’s Board of Directors. Both individuals bring extensive senior healthcare-focused leadership experience, Ms. McHug
Research and Markets: EpiCast Report: Glaucoma – Epidemiology Forecast to 2023
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/z46fl6/epicast_report) has announced the addition of the “EpiCast Report: Glaucoma – Epidemiology Forecast to 2023” report to their offering. Glaucoma is a common…
Second Sight Appoints Will McGuire as President and CEO
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that provide some useful vision to blind patients, today anno…
Eleven Biotherapeutics Announces Executive Change
CAMBRIDGE, Mass.–(BUSINESS WIRE)–John McCabe, Eleven’s VP, Finance and Business Operations, is promoted to assume the roles of Principal Financial Officer and Principal Accounting Officer, reporting directly to Abbie Celniker, PhD.
Research and Markets: Posterior Uveitis – Pipeline Review, H1 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/t2fxnx/posterior_uveitis) has announced the addition of the “Posterior Uveitis – Pipeline Review, H1 2015” report to their offering. This report provides comprehe…
Renaissance Adds to Nationally Recognized Dental and Vision Plans in South Carolina With New Hire
INDIANAPOLIS–(BUSINESS WIRE)–Renaissance is adding nationally recognized dental and vision plans in South Carolina with new hire, Dan Pruitt.
pSivida CEO to Present at ISOPT Clinical Meeting in Berlin in July 2015
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida CEO to present at ISOPT clinical meeting in Berlin in July 2015
Visioneering Technologies, Inc., Taps MidSouth Premier Ophthalmics as Exclusive Distributor for NaturalVue™ Lenses
ALPHARETTA, Ga.–(BUSINESS WIRE)–Visioneering Technologies, Inc., (VTI), manufacturers of NaturalVue™ Multifocal 1 Day Daily Disposable Soft Contact Lenses, has tapped MidSouth Premier Ophthalmics as exclusive distributor
ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis at the 19th International Congress of Parkinson’s Disease and Movement Disorders
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the presentation of integrated efficacy and tolerability data from its Phase III program with NUPLAZID™ (pimavanserin) at the 19th International Congress of Parkinson’s Disease and Movement Disorders held in San Diego. “Data from the integrated analysis o
Clearside Biomedical, Inc. Announces Favorable End-of-Phase 2 Review with the FDA
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, Inc., a biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced a favorable End-of-Phase 2 review with the U.S. Food and Drug Admi…
Ocugen to Present at BIO International Convention
AURORA, Colo.–(BUSINESS WIRE)–Ocugen, Inc. today announced leadership updates and that company Chairman and CEO Dr. Shankar Musunuri will present at BIO International Convention this week in Philadelphia.
Glaukos Corporation Announces Launch of Initial Public Offering
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced tod…
Research and Markets: Ocular Hypertension – Pipeline Review, H1 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/jrdqcj/ocular) has announced the addition of the “Ocular Hypertension – Pipeline Review, H1 2015” report to their offering. This report provides comprehensive inf…
LENSAR erhält CE-Kennzeichnung für fünf neue Leistungsanwendungsupgrades am LENSAR-Lasersystem
ORLANDO, Florida (USA)–(BUSINESS WIRE)–LENSAR Inc., ein globaler Führer in der Femtosekunden-Lasertechnologie für refraktive Kataraktchirurgie, hat heute mitgeteilt, dass es für eine Suite aus fünf neuen Anwendungstechnologien, die in das Vorzeigeprodukt des Unternehmens, das LENSAR® Laser System, integriert wurden, die CE-Kennzeichnung der Regulierungsbehörde der Europäischen Union erhalten hat. Als erste Femtosekunden-Laserkataraktplattform zur Ermöglichung der Automatisierung von Planungs-
LENSAR obtient le marquage CE pour cinq nouvelles mises à niveau d’application de performance du système laser LENSAR
ORLANDO, Floride–(BUSINESS WIRE)–LENSAR, Inc., un leader mondial en technologie laser femtoseconde de prochaine génération pour la chirurgie de la cataracte réfractive, a annoncé aujourd’hui que les régulateurs de l’Union européenne lui avaient accordé le marquage CE pour une série de cinq nouvelles technologies d’application intégrées au produit phare de la société, le système laser LENSAR®. En tant que première plateforme de cataracte laser femtoseconde à permettre l’automatisation des élém
LENSAR Receives CE Mark for Five New Performance Application Upgrades to the LENSAR Laser System
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc., announces receipt of the CE Mark for five application upgrades to the LENSAR® Laser System with Streamline™ for femtosecond cataract surgery.
Riassunto: LENSAR riceve il marchio CE per cinque nuovi aggiornamenti alle prestazioni dell’applicazione per il sistema laser LENSAR
ORLANDO, Florida–(BUSINESS WIRE)–LENSAR, Inc., leader a livello mondiale della tecnologia laser a femtosecondi di nuova generazione per la chirurgia refrattiva per cataratta, ha annunciato oggi di aver ricevuto il marchio CE da parte degli enti regolatori dell’Unione Europea per un pacchetto di cinque nuove tecnologie di applicazione integrate nel prodotto fiore all’occhiello della società, il sistema laser LENSAR®. Il testo originale del presente annuncio, redatto nella lingua di partenza, è
Research and Markets: Global Ophthalmics Partnering Deal Trends, Players and Financials 2010-2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/pftvgh/global) has announced the addition of the “Global Ophthalmics Partnering 2010-2015: Deal trends, players and financials” report to their offering. The Glob…
InSite Vision to Merge With Canadian Biotechnology Company QLT
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Inc. (OTCBB: INSV) today announced that it has reached a definitive agreement with QLT Inc. (NASDAQ: QLTI) (TSX: QLT) under which QLT will acquire InSite in an all-stock transaction that will create an ophthalmic specialty pharmaceutical company with a diversified portfolio of products, full R&D capabilities and innovative platform technologies. The transaction is expected to drive shareholder value by accelerating both companies’ development